Your current position:HOME > Products & Services > Tumor Gene Detection > Colorectal Cancer
Products & Services
Summary of Colorectal Cancer
Colorectal cancer is also called colon cancer, and it is one of the most common malignant gastrointestinal tumors at present in China. According to the latest statistic data, there were about 376,000 new cases of colorectal caner in our country in 2015, which have accounted for more than 1/6 of the global incidence cases of colorectal cancer. And in recent 10 years, the morbidity of colorectal cancer in China has been tending to increase.

  Scientific studies have verified that cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore in several kinds of cancers, it is regarded as the first choice of treatment for advanced cancer patients. As for different patients, the genovariation they carry also have a tremendous difference, such differences cause the different sensitivity and toxicity reaction of each patient with the same targeted drug. In the guideline of cancer in United States (NCCN) clearly recommend that patients with colorectal cancer must detect the status of genetic mutation of KRAS, NRAS and BRAF and so on before using Cetuximab.

The precision diagnosis is a prerequisite for precise medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by colorectal cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.

  The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. As more and more driver genes of colorectal cancer targets have been found, the traditional single detection technology can’t meet the current detection needs. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.
Colorectal core™

Gene detection of colorectal cancer for individualized medication

Burning Rock Colorectal core™ targeted at patients with colorectal cancer, by applying the advanced second generation sequencing technique, can comprehensively detects the drug-inhibited genovariation related to colorectal cancer, which clinically provides reference information of selection of individualized treatment for colorectal cancer.

Genes covered in Colorectal core™


Targeted drugs covered in Colorectal core™


More comprehensive targeted guideline:

Colorectal core™ comprehensively detects drug-inhibited target gene suggested in colorectal cancer NCCN guideline, drug-inhibited target spot researched in the phase Ⅱ/Ⅲ clinical trial of colorectal cancer and approved drug-inhibited target spot of all kinds of cancers, provides the most comprehensive genetic detecting of individualized medication  of colorectal cancer.

More accurate gene mutation detection related to colorectal cancer:

The gene detection Panel based on the second generation sequencing technology optimized by Burning Rock Dx, can detect 4 types of variation types at one time (mutation, insertion and deletion, fusion, amplification, etc.), at the same time, applies deep sequencing to deeply cover trace genovariation, so as to provide full view of the precise genovariation although samples are limited. On the one hand, the parallel detecting with the polygenic high sensitivity  improves the detection rate of drug-inhibited genovariation, which is able to miss opportunity of dedication; On the other hand, the complete coverage of exons can detect the hot spots and rare even unknown genovariation at the same time in one detection, detect related drug-resistant mutation while discovering drug sensitivity mutation(such as KRAS and ALK point mutation),  having an accurate reflection of the sensitivity and drug resistance information of the patients after the usage of medication.

More professional detection report interpretation:

Buring Rock Dx, having the patented automated analysis system, is also the domestic third party detecting company only owning the professional medical department. The improved software and hardware resources ensures the accuracy of every detection report, which provides accurate and comprehensive basis of designing more reasonable individualized treatment scheme for doctors.

Applicable Populations


Sample Requirements

Operation organization and biopsy samples, fresh tissues or paraffin embedding samples are available.

Service Cycle

After sample inspection, detailed detection report will be issued in 10 natural days.

Service Procedure

Cases Sharing